School of Medicine


Showing 1,281-1,290 of 4,925 Results

  • George A. Fisher Jr.

    George A. Fisher Jr.

    Colleen Haas Chair in the School of Medicine

    Current Research and Scholarly InterestsClinical expertise in GI cancers with research which emphasizes Phase I and II clinical trials of novel therapies but also includes translational studies including biomarkers, molecular imaging, tumor immunology and development of immunotherapeutic trials.

  • Paul Graham Fisher, MD

    Paul Graham Fisher, MD

    Beirne Family Professor of Pediatric Neuro-Oncology, Professor of Pediatrics and, by courtesy, of Neurosurgery and of Epidemiology and Population Health
    On Partial Leave from 07/15/2024 To 07/13/2025

    Current Research and Scholarly InterestsClinical neuro-oncology: My research explores the epidemiology, natural history, and disease patterns of brain tumors and other cancers in childhood, as well as prospective clinical trials for treating these neoplasms. Research interests also include neurologic effects of cancer and its therapies.

  • Philip Andrew Fisher

    Philip Andrew Fisher

    Diana Chen Professor of Early Childhood Learning and Professor, by courtesy, of Pediatrics

    BioDr. Philip Fisher is the Diana Chen Professor of Early Childhood Learning in the Graduate School of Education at Stanford. His research, which has been continuously funded by the National Institutes of Health since 1999, focuses on developing and evaluating scalable early childhood interventions in communities, and on translating scientific knowledge regarding healthy development under conditions of adversity for use in social policy and programs. He is particularly interested in the effects of early stressful experiences on children's neurobiological and psychological development, and in prevention and treatment programs for improving children's functioning in areas such as relationships with caregivers and peers, social-emotional development, and academic achievement. He is currently the lead investigator in the ongoing RAPID-EC project, a national survey on the well-being of households with young children during the COVID-19 pandemic. Dr. Fisher is also interested in the brain's plasticity in the context of therapeutic interventions. He is the developer of a number of widely implemented evidence-based interventions for supporting healthy child development in the context of social and economic adversity, including Treatment Foster Care Oregon for Preschoolers (TFCO-P), Kids in Transition to School (KITS), and Filming Interactions to Nurture Development (FIND). He has published over 200 scientific papers in peer reviewed journals. He is the recipient of the 2012 Society for Prevention Research Translational Science Award, and a 2019 Fellow of the American Psychological Society.

  • Robert Fisher, MD, PhD

    Robert Fisher, MD, PhD

    The Maslah Saul, MD, Professor and Professor, by courtesy, of Neurosurgery

    Current Research and Scholarly InterestsDr. Fisher is interested in clincal, laboratory and translational aspects of epilepsy research. Prior work has included: electrical deep brain stimulation for epilepsy, studied in laboratory models and clinical trials; drug delivery to a seizure focus; mechanisms of absence epilepsy studied with in vitro slices of brain thalamus; hyperthermic seizures; diagnosis and treatment of non-epileptic seizures, the post-ictal state; driving and epilepsy; new antiepileptic drugs; surgery for epilepsy.

  • Daniel Owen Fishman

    Daniel Owen Fishman

    Clinical Assistant Professor, Psychiatry and Behavioral Sciences - Medical Psychiatry

    BioAfter graduating from Vanderbilt Medical School, Dr. Fishman completed the Psychiatry Residency Program at University of Pittsburgh Medical Center, where he served as Chief Resident and was lauded with the program’s sole Teaching Award. Thereafter, Dr. Fishman completed the Consultation-Liaison Psychiatry Fellowship also at the University of Pittsburgh Medical Center. During his training, he also served as Chief Fellow was elected into Alpha Omega Alpha, Honors Medical Society. In the subsequent years, Dr. Fishman practiced as a consultation and liaison psychiatrist, simultaneously serving both academic and community hospitals in the Greater Pittsburgh Area. In his outpatient clinic, he managed and treated patients with complex issues linking the domains of neurology and psychiatry, and specialized in nonepileptic episodes.

    Dr. Fishman joined the faculty of Stanford University School of Medicine in 2020 as a Clinical Assistant Professor of Psychiatry and Behavioral Sciences. Since his appointment, Dr. Fishman has led medical psychiatry services on the medical/surgical units, intensive care units and in the emergency department at Stanford Hospital to provide psychiatric care for patients with acute diagnoses and provide graduate medical education to psychiatry, internal medicine, palliative care, oncology, and neurology trainees. His work on developing a framework for evidence-based best practice guidelines was recognized with a 2020 DLIN/Fischer finalist award.

    Dr. Fishman is the appointed Chief of the Inpatient Proactive Psycho-Oncology Service, a service designed to proactively identify patients with psychopathology or who will require psychiatric intervention during their hospitalization. The service helps prevent development and escalation of psychopathology in the inpatient blood and marrow transplant and other cancer populations. His outpatient work is primarily as a psychiatric oncologist at the Stanford Cancer Center where he provides psychiatric consultation services and collaborates closely with his oncology colleagues to deliver comprehensive cancer care.

    His clinical and scholarly interests include the interface of medicine and psychiatry, psycho-oncology, catatonia, neuropsychiatry, collaborative care models, psychotherapy for the medically ill, interdisciplinary and graduate medical education.

  • Matthew Fitzgerald, PhD

    Matthew Fitzgerald, PhD

    Associate Professor of Otolaryngology - Head & Neck Surgery (OHNS)

    Current Research and Scholarly InterestsMy research encompasses several translational projects. One focus is to modify the routine audiologic test battery such that it places equal weight on hearing acuity and hearing function. This work includes measures of speech in noise, or electrophysiologic responses such as the FFR. I also explore tools to better assess and maximize performance in users of hearing aids and cochlear implants. Finally, I am also investigating the benefits of telemedicine, and new treatments for tinnitus.

  • Peter Fitzgerald, MD, PhD

    Peter Fitzgerald, MD, PhD

    Professor (Research) of Medicine (Cardiovascular), Emeritus

    BioDr. Peter Fitzgerald is the Director of the Center for Cardiovascular Technology and Director of the Cardiovascular Core Analysis Laboratory (CCAL) at Stanford University Medical School. He is an Interventional Cardiologist and has a PhD in Engineering. He is Professor in both the Departments of Medicine and Engineering (by courtesy) at Stanford. Presently, Dr. Fitzgerald’s laboratory includes 17 postdoctoral fellows and graduate engineering students focusing on state-of-the-art technologies in Cardiovascular Medicine. He has led or participated in over 175 clinical trials, published over 550 manuscripts/chapters, and lectures worldwide. He has trained over 150 post-docs in Engineering and Medicine in the past decade. In addition, he heads the Stanford/Asia MedTech innovation program.
    Dr. Fitzgerald has been principle/founder of twenty-one medical device companies in the San Francisco Bay Area. He has transitioned fourteen of these start-ups to large medical device companies. He serves on several boards of directors, advised dozens of medical device startups as well as multinational healthcare companies in the design and development of new diagnostic and therapeutic devices in the cardiovascular arena. In 2001, Peter was on the founding team of LVP Capital, a venture firm, focused on medical device and biotechnology start-ups in San Francisco. In 2009, he co-founded TriVentures, which is an incubator/venture fund for early stage medical technology in Israel.